“The long-term survival benefit achieved with Keytruda as a single agent in this study is a great example of the progress we have made in lung cancer to provide patients with more time without disease progression and a chance at a longer life,” Reck said....
Data from the study showed that the combination of Keytruda plus chemotherapy led to a significant improvement in both overall survival (OS) and progression-free survival rates compared with patients receiving only chemotherapy in the given indication. 对鳞状NSCLC患者的批准是基于III期Keynote-407研究的...
Lung cancer is the No. 1 killer among cancer deaths in Korea. Treatment guidelines in other countries recommended the first-line immunotherapy as the standard treatment based on improved survival rates. Still, in Korea, such immunotherapy was reimbursed only in the second or higher-line treatment ...
In general, PD-1 immune checkpoint inhibitors like Keytruda have been shown to significantly prolong overall survival (OS) in some patients over a wide range of cancer types. But it’s important to know that these cancer treatments do not work for everyone. The success rate of Keytruda depends...
Overall survival rates at 24 months were 30.6% for the Keytruda group versus 26.4% for the control. The study concluded that adding Keytruda for these TKI-resistant, EGFR-mutant NSCLC patients did not meet the primary endpoints of prolonging progression-free survival or overall survival. These ...
Non-small cell lung cancer is the most common type of lung cancer, accounting for about 81% of all cases. In the U.S., the overall five-year survival rate for patients diagnosed with lung cancer is 25%, whi...
Finding cancer at an earlier stage may give patients a greater chance of long-term survival. Many cancers are considered most treatable and potentially curable in their earliest stage of disease. Building on the strong understand...
Small cell lung cancer - as a single agent for subsequent therapy of relapsed or progressive disease; Vaginal cancer - for treatment of vaginal cancer whenanyof the following criteria are met: The requested medication will be used in combination with cisplatin or carboplatin, paclitaxel, and with ...
said the benefit of the Opdivo-Yervoy combo “has been well established in phase 3 trials across lung cancer, melanoma, renal cell carcinoma and mesothelioma,” that these studies “clearly demonstrate that combining Yervoy with Opdivo can help patients achieve durable, long-term surviva...
“The majority of patients withgastric cancerare diagnosed at an advanced stage, at which point they face a poor prognosis with a five-year survival rate of 6%,” said Dr. Zev A. Wainberg, professor of medicine at University of California, Los Angeles School of Medicine and co...